148 related articles for article (PubMed ID: 37940048)
1. A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state.
Teranishi-Ikawa Y; Soeda T; Koga H; Yamaguchi K; Kato K; Esaki K; Asanuma K; Funaki M; Ichiki M; Ikuta Y; Ito S; Joyashiki E; Komatsu SI; Muto A; Nishimura K; Okuda M; Sanada H; Sato M; Shibahara N; Wakabayashi T; Yamaguchi K; Matsusaki A; Sampei Z; Shiraiwa H; Konishi H; Kawabe Y; Hattori K; Kitazawa T; Igawa T
J Thromb Haemost; 2024 Feb; 22(2):430-440. PubMed ID: 37940048
[TBL] [Abstract][Full Text] [Related]
2. Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence.
Leksa NC; Aleman MM; Goodman AG; Rabinovich D; Peters R; Salas J
J Thromb Haemost; 2019 Jul; 17(7):1044-1052. PubMed ID: 30887655
[TBL] [Abstract][Full Text] [Related]
3. Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A.
Josset L; Leuci A; Janbain M; De-Wreede A; Desage S; Lienhart A; Bin V; Lebert D; Delavenne X; Dargaud Y
J Thromb Haemost; 2024 Jul; 22(7):1857-1866. PubMed ID: 38583717
[TBL] [Abstract][Full Text] [Related]
4. Emicizumab-mediated hemostatic function assessed by thrombin generation assay in an in vitro model of factor VIII-depleted thrombophilia plasma.
Yada K; Ogiwara K; Shimonishi N; Nakajima Y; Soeda T; Kitazawa T; Nogami K
Int J Hematol; 2024 Feb; 119(2):109-118. PubMed ID: 38112996
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
[TBL] [Abstract][Full Text] [Related]
6. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro.
Minami H; Nogami K; Yada K; Ogiwara K; Furukawa S; Soeda T; Kitazawa T; Shima M
J Thromb Haemost; 2019 Jan; 17(1):126-137. PubMed ID: 30444568
[TBL] [Abstract][Full Text] [Related]
7. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
Yada K; Nogami K; Ogiwara K; Shida Y; Furukawa S; Yaoi H; Takeyama M; Kasai R; Shima M
Int J Hematol; 2019 Oct; 110(4):419-430. PubMed ID: 31254165
[TBL] [Abstract][Full Text] [Related]
8. An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A.
Takeyama M; Nogami K; Matsumoto T; Noguchi-Sasaki M; Kitazawa T; Shima M
J Thromb Haemost; 2020 Apr; 18(4):825-833. PubMed ID: 31984625
[TBL] [Abstract][Full Text] [Related]
9. Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab.
Yada K; Nogami K
Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1148-1154. PubMed ID: 32237902
[TBL] [Abstract][Full Text] [Related]
10. Clot waveform analysis for perioperative hemostatic monitoring in a hemophilia A patient on emicizumab undergoing liver transplantation.
Awane M; Wakui M; Ozaki Y; Kondo Y; Oka S; Fujimori Y; Yatabe Y; Arai T; Yamada Y; Hori S; Obara H; Hasegawa Y; Matsushita H
Clin Chim Acta; 2023 Apr; 544():117339. PubMed ID: 37076096
[TBL] [Abstract][Full Text] [Related]
11. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
[TBL] [Abstract][Full Text] [Related]
12. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens.
Kitazawa T; Esaki K; Tachibana T; Ishii S; Soeda T; Muto A; Kawabe Y; Igawa T; Tsunoda H; Nogami K; Shima M; Hattori K
Thromb Haemost; 2017 Jun; 117(7):1348-1357. PubMed ID: 28451690
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics Monitoring of Emicizumab in Patients with Hemophilia A.
Bertaggia Calderara D; Marchi Cappelletti R; Batista Mesquita Sauvage AP; Durual S; Gomez FJ; Zermatten MG; Aliotta A; Casini A; Alberio L
Thromb Haemost; 2023 Oct; 123(10):955-965. PubMed ID: 37336473
[TBL] [Abstract][Full Text] [Related]
14. [Emicizumab, a bispecific antibody mimicking factor VIII: a novel alternative therapy for hemophilia A with inhibitors].
Nogami K
Rinsho Ketsueki; 2019; 60(5):475-479. PubMed ID: 31168016
[TBL] [Abstract][Full Text] [Related]
15. NXT007-mediated hemostatic potential is suppressed by activated protein C-catalyzed inactivation of activated factor V.
Nakajima Y; Ogiwara K; Inaba K; Kitazawa T; Nogami K
Res Pract Thromb Haemost; 2024 Jan; 8(1):102271. PubMed ID: 38115953
[TBL] [Abstract][Full Text] [Related]
16. Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A.
Takeyama M; Matsumoto N; Abe H; Harada S; Ogiwara K; Furukawa S; Shimonishi N; Nakajima Y; Yada K; Soeda T; Nogami K
Pediatr Blood Cancer; 2023 Oct; 70(10):e30590. PubMed ID: 37467119
[TBL] [Abstract][Full Text] [Related]
17. Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.
Yada K; Nogami K; Shinozawa K; Kitazawa T; Hattori K; Amano K; Fukutake K; Shima M
Br J Haematol; 2018 Oct; 183(2):257-266. PubMed ID: 30125997
[TBL] [Abstract][Full Text] [Related]
18. Chromogenic Factor VIII Assay for Patients with Hemophilia A and on Emicizumab Therapy.
Yacoub OA; Duncan EM
Methods Mol Biol; 2023; 2663():597-610. PubMed ID: 37204739
[TBL] [Abstract][Full Text] [Related]
19. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
[TBL] [Abstract][Full Text] [Related]
20. [Emicizumab: a paradigm shift in hemophilia treatment].
Nogami K
Rinsho Ketsueki; 2020; 61(5):536-541. PubMed ID: 32507821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
